OPEN ACCESS Freely available online

Pediatrics & Therapeutics

ISSN: 2161-0665

Short Communication

Enigma of Kawasaki Disease in Infants

Michael Raoult*

Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, Scotland, UK

DESCRIPTION

Kawasaki disease is a rare but potentially serious condition that primarily affects infants and young children. Characterized by inflammation of the blood vessels, Kawasaki disease can lead to complications such as coronary artery aneurysms if left untreated. Despite decades of research, the exact cause of Kawasaki disease remains unknown, making it a challenging condition to diagnose and manage. In this article, we delve into the intricacies of Kawasaki disease in infants, exploring its symptoms, diagnosis, treatment, and the ongoing efforts.

Kawasaki disease overview

First identified in Japan in the 1960s by Dr. Tomisaku Kawasaki, Kawasaki disease, also known as mucocutaneous lymph node syndrome [1], is a systemic vasculitis that primarily affects young children, with infants under the age of one being particularly vulnerable. While the exact cause of Kawasaki disease remains elusive, it is believed to involve a combination of genetic, immunological, and environmental factors.

Kawasaki disease typically presents with a constellation of symptoms, including prolonged fever, rash, red eyes, swollen lymph nodes, and changes in the mouth and lips, such as a strawberry tongue or cracked lips [2]. In severe cases, Kawasaki disease can lead to inflammation of the coronary arteries, which supply blood to the heart, potentially resulting in coronary artery aneurysms or other cardiovascular complications [3].

Diagnosis and treatment

Diagnosing Kawasaki disease can be challenging due to its nonspecific symptoms and lack of definitive diagnostic tests [4]. The diagnosis is primarily based on clinical criteria established by the American Heart Association, which include fever lasting five or more days accompanied by at least four of the following criteria:

Bilateral conjunctival injection (redness of the eyes without discharge) Changes in the lips and mouth, such as redness, cracking, or a strawberry tongue. Rash, often erythematous and diffuse, affecting the trunk and extremities. Swelling or redness of the hands and feet, followed by peeling of the skin. Cervical lymphadenopathy (enlarged lymph nodes). In addition to meeting the clinical criteria, other laboratory tests, such as complete blood count, inflammatory markers, and echocardiography, may be performed to assess for signs of inflammation and cardiovascular involvement [5].

The treatment of Kawasaki disease typically involves Intravenous Immunoglobulin (IVIG) therapy and aspirin to reduce inflammation and prevent coronary artery complications. IVIG is administered to modulate the immune response and reduce the risk of coronary artery aneurysms, while aspirin helps alleviate fever and inflammation. In cases of refractory or severe disease, additional treatments such as corticosteroids or biologic agents may be considered [6].

Managing kawasaki disease in infants

Managing Kawasaki disease in infants presents unique challenges due to their young age and vulnerability. Infants may present with atypical symptoms or be unable to communicate their discomfort, making early recognition and diagnosis crucial for timely intervention [7].

Pediatricians and healthcare providers play a vital role in recognizing the signs and symptoms of Kawasaki disease in infants and initiating prompt treatment to prevent complications. Close monitoring of cardiac function, including serial echocardiography, is essential for detecting coronary artery abnormalities and guiding treatment decisions.

Furthermore, ongoing follow-up care is essential for infants with Kawasaki disease to monitor their cardiovascular health and assess for long-term complications. Children with coronary artery aneurysms may require lifelong cardiology follow-up and interventions to prevent thrombosis, stenosis, or other complications [8].

Correspondence to: Michael Raoult, Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, Scotland, UK, E-mail: Raoult@mic.co.uk

Received: 01-Feb-2024, Manuscript No. PTCR-24-30218;**Editor assigned:** 03-Feb-2024, Pre QC No. PTCR-24-30218 (PQ);**Reviewed:** 16-Feb-2024, QC No. PTCR-24-30218; **Revised:** 23-Feb-2024, Manuscript No. PTCR-24-30218 (R); **Published:** 01-Mar-2024, DOI: 10.35248/2161-1068.24.14.548

Citation: Raoult M (2024) Enigma of Kawasaki Disease in Infants. Pediatr Ther.14:548

Research and future directions

Despite significant advancements in the understanding and treatment of Kawasaki disease, many questions remain unanswered, particularly regarding its etiology and the mechanisms underlying coronary artery involvement. Research efforts are underway to identify genetic predispositions, environmental triggers, and immune dysregulation that may contribute to the development of Kawasaki disease [9].

Additionally, there is a growing interest in developing novel therapeutic strategies and biomarkers for Kawasaki disease, with the aim of improving diagnostic accuracy, predicting disease severity, and optimizing treatment outcomes [10]. Collaborative research initiatives, multicenter clinical trials, and international registries are essential for advancing our understanding of Kawasaki disease and improving outcomes for affected infants and children.

CONCLUSION

Kawasaki disease remains a complex and enigmatic condition that poses significant challenges for infants, families, and healthcare providers. Early recognition, timely intervention, and close monitoring are critical for preventing complications and optimizing outcomes for infants with Kawasaki disease. Through ongoing research, collaboration, and advocacy, we can continue to unravel the mysteries of Kawasaki disease, improve diagnostic and treatment strategies, and ultimately enhance the care and well-being of affected infants worldwide.

REFERENCES

1. Bradley DJ, Glode MP. Kawasaki disease. The mystery continues. West J Med. 1998;168(1):23-29.
2. Burns JC, Kushner HI, Bastian JF, Shike H, Shimizu C, Matsubara T, et al.. Kawasaki disease: A brief history. Pediatrics. 2000;106(2):e27.
3. Burns JC. The etiologies of Kawasaki disease. J Clin Invest. 2024;134(5).
4. Kushner HI, Turner CL, Bastian JF, Burns JC. The narratives of Kawasaki disease. Bull Hist Med. 2004:410-439.
5. Rowley AH. Is Kawasaki disease an infectious disorder?. Int J Rheum Dis. 2018;21(1):20-25.
6. Melish ME. The history of kawasaki disease: A personal perspective. Kawasaki Disease: Current Understanding of the Mechanism and Evidence-Based Treatment. 2017:3-9.
7. Lee W, Cheah CS, Suhaini SA, Azidin AH, Khoo MS, Ismail NA, et al. Clinical manifestations and laboratory findings of Kawasaki disease: Beyond the classic diagnostic features. Medicina. 2022;58(6): 734.
8. Barron KS. Kawasaki disease in children. Curr Opin Rheumatol. 1998;10(1):29-37.
9. Sharma D, Singh S. Kawasaki disease-A common childhood vasculitis. Indian J Rheumatol. 2015;10(S1):S78-S83.
10. Dezfouli SM, Salehi S, Khosravi S. Pathogenic and therapeutic roles of cytokines in Kawasaki diseases. Clin Chim Acta. 2022;532:21-28.